Millipore Sigma Vibrant Logo

390900 4-Hydroxyphenylretinamide - CAS 65646-68-6 - Calbiochem

A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity.

4-Hydroxyphenylretinamide - CAS 65646-68-6 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: Fenretinide, 4HPR, N-(4-Hydroxyphenyl)-all-trans Retinamide

Primary Target: Active in the prevention and treatment of a variety of neoplasms in animals.
View This Product on Sigma-Aldrich
390900
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
65646-68-6C₂₆H₃₃NO₂

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
390900-5MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits human breast cancer, prostate adenocarcinoma, and ovarian carcinoma cell proliferation. Inhibits angiogenesis as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.
      Catalogue Number390900
      Brand Family Calbiochem®
      SynonymsFenretinide, 4HPR, N-(4-Hydroxyphenyl)-all-trans Retinamide
      References
      ReferencesFormelli, F., et al. 1996. FASEB J. 10, 1014.
      Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.
      Delia, D., et al. 1993. Cancer Res. 53, 6036.
      Pienta, K.J., et al. 1993. Cancer Res. 53, 224.
      Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.
      McCarthy, D.J., et al. 1987. Cancer Res. 47, 5014.
      Moon, R.C., et al. 1979. Cancer Res. 39, 1339.
      Product Information
      CAS number65646-68-6
      ATP CompetitiveN
      FormOrange solid
      Hill FormulaC₂₆H₃₃NO₂
      Chemical formulaC₂₆H₃₃NO₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetActive in the prevention and treatment of a variety of neoplasms in animals.
      Purity≥97% by TLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSVH6420000
      Safety Information
      R PhraseR: 20/21/22-36/37/38-60-61

      Harmful by inhalation, in contact with skin and if swallowed.
      Irritating to eyes, respiratory system and skin.
      May impair fertility.
      May cause harm to the unborn child.
      S PhraseS: 26-36/37/39-45

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      390900-5MGCN 04055977190007

      Documentation

      4-Hydroxyphenylretinamide - CAS 65646-68-6 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      4-Hydroxyphenylretinamide - CAS 65646-68-6 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      390900

      参考資料

      参考資料の概要
      Formelli, F., et al. 1996. FASEB J. 10, 1014.
      Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.
      Delia, D., et al. 1993. Cancer Res. 53, 6036.
      Pienta, K.J., et al. 1993. Cancer Res. 53, 224.
      Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.
      McCarthy, D.J., et al. 1987. Cancer Res. 47, 5014.
      Moon, R.C., et al. 1979. Cancer Res. 39, 1339.

      カタログ

      タイトル
      Caspases and other Apoptosis Related Tools Brochure
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-March-2008 JSW
      SynonymsFenretinide, 4HPR, N-(4-Hydroxyphenyl)-all-trans Retinamide
      DescriptionA synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits proliferation in cell lines of human breast cancer, prostate adenocarcinoma, and ovarian carcinoma. Inhibits angiogenesis, as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.
      FormOrange solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number65646-68-6
      RTECSVH6420000
      Chemical formulaC₂₆H₃₃NO₂
      Structure formulaStructure formula
      Purity≥97% by TLC
      SolubilityAcetone, DMSO (25 mg/ml), or Ethanol
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      Merck USA index14, 3998
      ReferencesFormelli, F., et al. 1996. FASEB J. 10, 1014.
      Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.
      Delia, D., et al. 1993. Cancer Res. 53, 6036.
      Pienta, K.J., et al. 1993. Cancer Res. 53, 224.
      Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.
      McCarthy, D.J., et al. 1987. Cancer Res. 47, 5014.
      Moon, R.C., et al. 1979. Cancer Res. 39, 1339.